Navigation Links
Cell Therapeutics to Resume Trading on MTA and NASDAQ
Date:2/17/2009

SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective with the open of trading in Italy on February 18, 2009. Based on the foregoing and CTI's communications with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ on February 18, 2009.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that that NASDAQ may not re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ within the anticipated time frame, the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... The results from the American Cancer Society’s newest report on ... patients: incidents of cancer is down as is the likelihood of prostate cancer patients ... dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per 100K ...
(Date:1/24/2017)... ... 24, 2017 , ... American Family Care (AFC) has opened a new 4,000+ ... for residents in the area. The Bedford clinic will be the nineteenth location opened ... by Dave Adams and Dr. Kristina Orio. Adams and Orio also independently own and ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Who Would Have Dreamed: A Novel of Miracles”: a beautiful ... tried to understand its purpose in her life. “Who Would Have Dreamed: A Novel of ... and a love of writing. , Sharon shares that she started her spiritual ...
(Date:1/24/2017)... ... 24, 2017 , ... “The Octagon of Spiritual Balances”: a guide for ... the creation of published author, Pastor Bernard J. Weathers, pastor of Word of Faith ... in religious education and a master degree in theology. , ““The Octagon of Spiritual ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... FRANCISCO , January 24, 2017 The global  ... USD 239.8 billion by 2025, based on a new report by Grand ... cancer is projected to drive the market over the forecast period. Advancements ... are also estimated to boost growth.  Continue ... ...
(Date:1/24/2017)... , Jan. 23, 2017 Optoelectronic ... and control light. The interaction of these components ... in a wide range of applications. These components ... and defense, telecommunications, and healthcare among others. ... owing to its low power consumption, reliability, scalability, ...
Breaking Medicine Technology: